
    
      This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate
      safety and tolerability and efficacy of VS-6766 versus VS-6766 in combination with defactinib
      in subjects with KRAS-MT NSCLC following treatment with an appropriate platinum-based regimen
      and an approved immune checkpoint inhibitor (CPI).
    
  